Olaparib in ovarian cancer with BRCA mutation

被引：5

作者：

Pujade-Lauraine, Eric ^{[1
]}

Combe, Pierre ^{[2
]}

机构：

[1] GH Paris Ctr, Ctr Canc Femme & Rech Clin, F-75181 Paris 04, France

[2] Hop Europeen Georges Pompidou, Serv Oncol Med, F-75015 Paris, France

来源：

BULLETIN DU CANCER | 2015年 / 102卷 / 06期

关键词：

BRCA; Ovarian cancer; Olaparib; PARP;

D O I：

10.1016/S0007-4551(15)31221-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With 4500 new cases and 3200 death each year, ovarian cancer is the first cause of mortality for gynecological cancer in France. Without any efficient screening, it is usually diagnosed around the age of 60 years at an advanced stage. The emergence of olaparib, a new targeted therapy, represents a major opportunity.

引用

页码：S82 / S84

页数：3

共 50 条

[11] Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer
Tewari, Krishnansu S.
Eskander, Ramez N.
Monk, Bradley J.
CLINICAL CANCER RESEARCH, 2015, 21 (17) : 3829 - 3835
[12] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm)
Ledermann, Jonathan A.
Harter, Philipp
Gourley, Charlie
Friedlander, Michael
Vergote, Ignace
Rustin, Gordon J. S.
Scott, Clare L.
Meier, Werner
Shapira-Frommer, Ronnie
Safra, Tamar
Matei, Daniela
Fielding, Anitra
Macpherson, Euan
Dougherty, Brian
Juergensmeier, Juliane M.
Orr, Maria
Matulonis, Ursula
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[13] BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
Manchana, Tarinee
Tantbirojn, Patou
Pohthipornthawat, Natkrita
GYNECOLOGIC ONCOLOGY REPORTS, 2020, 33
[14] BRCA2 reversion mutation confers resistance to olaparib in breast cancer
Yamamoto, Shinya
Kawashima, Kei
Fujiwara, Yoshie
Adachi, Shoko
Narui, Kazutaka
Hosaka, Chiaki
Takahashi, Rina
Tsuyuki, Sho
Sugimori, Makoto
Tanoshima, Miki
Sasamoto, Mahato
Oshi, Masanori
Yamada, Akimitsu
Kunisaki, Chikara
Endo, Itaru
CLINICAL CASE REPORTS, 2023, 11 (06):
[15] Experience with olaparib in the treatment of recurrent ovarian epithelial cancer with mutations in the BRCA 1 and BRCA 2 genes
Erik, Skof
ONKOLOGIJA, 2021, 25 (01) : 12 - 16
[16] Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated Ovarian Cancer
Saleh, Naveed
Copur, Mehmet Sitki
ONCOLOGY-NEW YORK, 2019, 33 (07): : 293 - 294
[17] Olaparib promotes FABP4 expression and reduces antitumor effect in ovarian cancer cells with a BRCA1 mutation
Huang, Wei
Meng, Hongxue
Xu, Ye
Huang, Lan
Lou, Ge
ONCOLOGY LETTERS, 2025, 29 (02)
[18] Breast Cancer Following Ovarian Cancer in BRCA Mutation Carriers
Gangi, Alexandra
Cass, Ilana
Paik, Daniel
Barmparas, Galinos
Karlan, Beth
Dang, Catherine
Li, Andrew
Walsh, Christine
Rimel, Bobbie J.
Amersi, Farin F.
JAMA SURGERY, 2014, 149 (12) : 1306 - 1313
[19] Breast cancer after ovarian cancer in BRCA mutation carriers
Nanez, A.
Powell, C. B.
Garcia, C.
GYNECOLOGIC ONCOLOGY, 2020, 159 : 256 - 256
[20] Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
Lee, Chee Khoon
Scott, Clare
Lindeman, Geoffrey J.
Hamilton, Anne
Lieschke, Elizabeth
Gibbs, Emma
Asher, Rebecca
Badger, Heath
Paterson, Robin
Macnab, Lauren
Kwan, Edmond Michael
Francis, Prudence A.
Boyle, Frances
Friedlander, Michael
BRITISH JOURNAL OF CANCER, 2019, 120 (03) : 279 - 285

← 1 2 3 4 5 →